Topvision Eye Specialist Berhad, (0332) Fair Value & Analysis
Healthcare · MY · Market cap 48.0M MYR
Fair value as of: Jun 26, 2026
Analysis
Topvision Eye Specialist Berhad, (0332) currently trades at 0.1550 MYR, while our model-based Fair Value estimate is 0.1300 MYR — implying the stock looks roughly 16.1% overvalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Topvision Eye Specialist Berhad, together with its subsidiaries, provides ophthalmology healthcare services in Malaysia. The company offers various eye care services for cataract, diabetic retinopathy, retinal detachment, glaucoma, age-related macular degeneration, pterygium, children's eye disorder, and other eye problems, including cornea ulcer, dry eyes, eyelid abscess, foreign body removal, subconjunctival hemorrhage, trauma, and viral conjunctivitis. It also engages in the provision of related medical consultancy services; marketing of eye supplements and health food products; retail sale of food and beverage; and import, export, and distribution of pharmaceuticals, medical devices and goods, cosmetics, and health supplements. The company was founded in 2010 and is headquartered in Shah Alam, Malaysia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Topvision Eye Specialist Berhad, (0332) undervalued?
What is the fair value of 0332?
What is the quality score of 0332?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.